As shown in Figure 1, increased LYNX1 expression was enriched in clinical stages III/IV (p = 0.787), primary therapy outcomes PR-CR (p = 0.320), cancer status with tumor (p = 0.319), histological grade G3/G4 (p = 0.967), tumor residual disease (RD) (p = 0.010), and anatomic neoplasm subdivision bilateral (p = 0.912). This evidence concerns the gene LYNX1 and neoplasm.